approval

InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

December 17, 2025 20:48 ET  | Source: InnoCare Pharma BEIJING, Dec. 17, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969;…

2 weeks ago

Clinikk Secures IRDAI Approval, Expands with Three New Health Hubs, and Launches its Diamond OPD Membership

BENGALURU, India, Dec. 17, 2025 /PRNewswire/ -- Healthtech company Clinikk, building India's first integrated health system, has received approval from…

2 weeks ago

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the…

3 weeks ago

Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly…

3 weeks ago

JASCAYD (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China

The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five…

3 weeks ago

Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program

November 28, 2025 20:13 ET  | Source: Rakovina Therapeutics Inc VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Rakovina…

1 month ago

HKUST Receives Government’s Approval to Establish a New Medical School

Dedicated to Nurturing a New Generation of DoctorsSupporting Hong Kong Become a Hub for Medical Innovation HONG KONG, Nov. 18,…

2 months ago

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the…

2 months ago

Junshi Biosciences Announces FDAs Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients

SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…

3 months ago

Gogo announces first Gogo Galileo FDX STC as ALOFT AeroArchitects receives approval covering Boeing Business Jet BBJ737-series aircraft.

Broomfield, CO., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Gogo (NASDAQ: GOGO) is pleased to confirm that the first Supplemental Type…

3 months ago